

## **DALIRESP (roflumilast) PRIOR AUTHORIZATION FORM**

Prior authorization guidelines for **COPD Agents** and **Quantity Limits/Daily Dose Limits**  
are available on Geisinger Health Plan's website at  
<https://healthplan.geisinger.org/pharmacy/pharmacy.aspx?strip=true&style=OneGeisinger>

|  |      |                  |                  |
|--|------|------------------|------------------|
| <input type="checkbox"/> New request <input type="checkbox"/> Renewal request    # of pages: _____ |      | Prescriber name: |                  |
| Name of office contact:  |      | Specialty:       |                  |
| Contact's phone number:  |      | NPI:             | State license #: |
| LTC facility contact/phone:  |      | Street address:  |                  |
| Beneficiary name:  |      | City/state/zip:  |                  |
| Beneficiary ID#:   | DOB: | Phone:           | Fax:             |

### **CLINICAL INFORMATION**

|                 |          |            |                     |
|-----------------|----------|------------|---------------------|
| Drug requested: |          | Strength:  | Directions:         |
| Quantity:       | Refills: | Diagnosis: | Dx code (required): |

#### **INITIAL Requests**

**Check all of the following that apply to the beneficiary and this request and SUBMIT DOCUMENTATION for each item.**

- ☐ Has COPD that is severe according to current GOLD guidelines and based on medical history, physical exam findings, and lung function tests
- ☐ Has chronic bronchitis with cough and sputum production for at least 3 months per year in 2 consecutive years
- ☐ Other causes of chronic airflow limitations have been excluded, such as asthma, bronchiectasis, heart failure, tuberculosis, etc.
- ☐ Experienced more than 2 COPD exacerbations per year that required an ED visit, hospitalization, or use of oral steroids
- ☐ Is using or cannot use maximum tolerated doses of the following (in either a single-ingredient or combination product – submit medication list):
  - ☐ Inhaled long-acting beta 2 agonist (LABA)
  - ☐ Inhaled long-acting anticholinergic/muscarinic antagonist (LAMA)
  - ☐ Inhaled corticosteroid (unless beneficiary has an eosinophil count <100 cells/microliter – *submit documentation of lab results*)
- ☐ Does not have moderate or severe liver impairment (Child-Pugh B or C)
- ☐ Does not have suicidal ideations
- ☐ Has a history of suicide attempt(s), bipolar disorder, major depressive disorder, schizophrenia, substance use disorder(s), anxiety disorder(s), borderline personality disorder, and/or antisocial personality disorder
  - ☐ Was evaluated and treated for this/these mental health condition(s) by a psychiatrist
  - ☐ Is a candidate for treatment with Daliresp as determined by a psychiatrist
- ☐ Does not have a history of the above mental health conditions
  - ☐ Had a mental health evaluation performed by the prescriber

#### **RENEWAL Requests**

**Check all of the following that apply to the beneficiary and this request and SUBMIT DOCUMENTATION for each item.**

- ☐ Frequency of COPD exacerbations has decreased since starting Daliresp
- ☐ Does not have suicidal ideations
- ☐ Was evaluated for new onset or worsening symptoms of anxiety and depression
  - ☐ If applicable, is being treated for these mental health conditions and determined to be a candidate for treatment with Daliresp

**Please submit to PromptPA <https://ghp.promptpa.com> OR fax to Geisinger Health Plan at 570-271-5610 the completed form with required clinical documentation.**

|                       |       |
|-----------------------|-------|
| Prescriber Signature: | Date: |
|-----------------------|-------|

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.